Remote Monitoring in Automated Peritoneal Dialysis Modifies the Clinical Course of Peritonitis: A Secondary Analysis of a Cluster Randomized Trial

Remote Monitoring in Automated Peritoneal Dialysis Modifies the Clinical Course of Peritonitis: A Secondary Analysis of a Cluster Randomized Trial | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Remote Monitoring in Automated Peritoneal Dialysis Modifies the Clinical Course of Peritonitis: A Secondary Analysis of a Cluster Randomized Trial Miguel Angel Cuevas-Budhart, Miguel Angel Trejo-Villeda, Marcela Avila Díaz, and 4 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-6993883/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Background: Peritonitis remains the most serious complication of peritoneal dialysis (PD), often resulting in hospitalization, technique failure, and increased mortality. Remote monitoring (RM) in automated peritoneal dialysis (APD) provides fast and opportune access to treatment data, potentially enabling earlier clinical intervention. Aim: To assess whether RM modifies the clinical course of peritonitis in APD patients by evaluating the time to first episode, hospitalization outcomes, and ultrafiltration (UF) dynamics. Methods: This secondary analysis of a cluster randomized controlled trial included 801 APD patients (403 with RM, 398 with conventional APD) followed from 2018 to 2020. A total of 95 patients with confirmed peritonitis were analyzed. Clinical variables and UF trends from the Sharesource® platform were assessed for the 10 days before and after the peritonitis diagnosis. Survival was evaluated using Kaplan–Meier curves and multivariable Cox regression models. Results: RM-APD patients experienced a significantly longer time to first peritonitis episode (13.3 vs. 11.7 months; p < 0.001). Although there were no significant differences in overall peritonitis incidence, hospitalization, or mortality rates, RM-APD patients showed improved post-hospitalization survival (p = 0.003) and lower therapy dropout after infection (p = 0.001). UF trends suggested a pre-infection decline, though not statistically significant. Conclusion: RM does not reduce peritonitis incidence but appears to enable earlier detection and improved outcomes, supporting a shift toward proactive management in APD. Future research should explore predictive algorithms based on RM-derived data to enhance peritonitis care. Remote monitoring Peritoneal Dialysis Peritonitis Remote Consultation Telemedicine Treatment Outcome Figures Figure 1 Figure 2 Figure 3 Figure 4 INTRODUCTION Infectious peritonitis is the most common complication in patients undergoing Peritoneal Dialysis (PD). It is the direct cause of death in >15% of PD deceased patients and the cause of approximately 16-20% of PD technique failure 1–3 . Peritonitis induces structural and functional damage in the peritoneal membrane even after a single episode, and severe or repeated infections can lead to membrane failure expressed by ultrafiltration (UF) failure 4,5 . Peritonitis has been a risk factor for mortality for a long time since it is an inductor of systemic inflammation and fluid overload secondary to derangement of UF, both associated with cardiovascular events 6,7 . Peritonitis rates vary widely, even up to 20 times, depending on non-modifiable factors such as age, diabetes and other comorbidities, education, and economic levels. Modifiable factors, such as the size of the dialysis program and attending population, staff training, and the success of the training programs for patients or their caregivers, also influence peritonitis rates 8 , 9 . Remote monitoring (RM), a recent advance in PD technology, allows the PD team to have closer surveillance of the patients; it allows the follow-up of prescribed treatment, as well as effective dialysis time, UF volume, inflow and drain of PD solutions patterns and patient’s skill in the management of the device. This information enables the early detection of clinically relevant issues, such as catheter permeability, peritonitis, treatment adherence, and UF problems. The correct use of this information enables the establishment of proactive actions that can decrease adverse events and hospitalizations 8 , 10–12 . The objective of this study was to evaluate the utility of remote monitoring in the clinical follow-up of peritonitis episodes in patients undergoing automated peritoneal dialysis by comparing clinical outcomes, ultrafiltration trends, and treatment response between those managed with or without remote monitoring. METHODOLOGY A secondary study was conducted among patients who participated in a cluster-randomized clinical trial 13 comparing Remote Monitoring of Automated Peritoneal Dialysis (RM-APD) with conventional Automated Peritoneal Dialysis (APD). The protocol of the original study was approved by the National Commission of Scientific Research and the local Research Committees of each hospital. Data from patients with a diagnosis of infectious peritonitis during the peritonitis phase (from 2018 to April 2020) were extracted from the central database of the two arms of the original study. The extracted information contains data on socio-demographic characteristics, baseline clinical data, as well as records of comorbidities and adverse events. The devices used in the original study were Homechoice Claria®, Baxter, S.A. de C.V., equipped with a device for RM (Sharesource® connectivity platform, Baxter Healthcare, Deerfield, IL, USA). Selected patients met the diagnostic criteria of peritonitis according to the ISPD, which include characteristic clinical data, such as abdominal pain, cloudy dialysis effluent, 3,14 leukocyte counts in dialysis effluent >100/µl (with a minimum permanence of 2 hours), >50% polymorph nuclear cells, and positive effluent culture 4 . The antibiotic prescription was based on the recommendations of the ISPD Clinical Guidelines. To evaluate the impact of peritonitis on ultrafiltration (UF), the date of clinical diagnosis was defined as the reference point. UF data were extracted from the Sharesource® platform over a 30-day post-diagnosis period. UF patterns were compared between patients who achieved clinical resolution and those who did not respond to antibiotic therapy. Statistical analysis Qualitative variables are expressed as simple frequencies and percentages. Quantitative continuous variables are expressed through their mean and standard deviation. Differences between groups were analyzed by Student´s “t” test or Squared Chi test according variable characteristics. To assess the effect of RM-APD on peritonitis episodes, incidence rates were analyzed at both the cluster and patient levels. Time-to-event outcomes, including time to first peritonitis episode, first hospitalization, and death, were evaluated using Kaplan–Meier survival curves and compared with the log-rank test. Multivariable Cox proportional hazards models were used to adjust for potential confounders, with results reported as hazard ratios (HR) and 95% confidence intervals (CI). UF dynamics during peritonitis episodes were analyzed using data extracted from the Sharesource® platform. Comparisons were made between patients who responded to antibiotic therapy and those who did not, as well as between patients with and without catheter dysfunction. Additional analyses included treatment adherence and the amount of dialysis time lost during the episode. RESULTS In the original study, 801 patients were enrolled: 398 in the APD group and 403 in the RM-APD group. Baseline clinical and biochemical characteristics were similar between groups. Figure 1 shows the patient selection and follow-up process. A total of 95 patients developed peritonitis and were included in the analysis. Follow-up continued until clinical recovery was achieved or, in the event of management needs, leave from the study was recommended. Several patients in the conventional APD group were shifted to CAPD to optimize antibiotic management, which limited the availability of Sharesource data for some cases. There were no significant differences between groups in the number of peritonitis episodes or their incidence rates. Table 1 presents the socio-demographic data for all patients with peritonitis and divided by study group. Except for age, there was no difference. The RM-APD group was ten years younger than the APD group. Table 2 presents the clinical parameters of both groups analyzed (APD and RM-APD). Most variables showed no difference except for neutrophils. The time (in months) from baseline until the first episode of peritonitis was significantly longer in the RM-APD group (14.81 months) compared to the APD group (11.20 months) (p <0.001), as shown in Figure 2. During the follow-up period, there were no differences between groups in the rates of first and subsequent peritonitis, hospitalization rates or days of hospitalization for peritonitis, or deaths secondary to peritonitis (Table 3). However, patient-level analyses revealed that the time from baseline to first hospitalization for peritonitis (p = 0.003) and dropout due to peritonitis (p = 0.001) were significantly shorter in the APD group, as shown in Figures 3 and 4, respectively. The data provided by the Sharesource platform is shown in Table 4. There were no significant differences between the groups. No relationship was found between episodes of peritonitis and exit site infections or tunnel infections, nor between peritonitis and mechanical problems with the catheter. No statistical significance was found regarding the variation of UF data provided by the Sharesource platform (β: 0.999; 95% CI: 0.998-1.001) during and after recovery from peritonitis. Finally, for the logistic regression analysis of factors associated with peritonitis recovery, no statistically significant associations were found. Factors include empirical monotherapy (β = 2.571; 95% CI: 0.721–9.167), empirical therapy covering both Gram-positive and Gram-negative bacteria (β = 0.400; 95% CI: 0.040–3.955), and targeted therapy (β = 0.727; 95% CI: 0.258–2.053). Additionally, ultrafiltration data from the Sharesource® platform showed no significant association (β = 0.999; 95% CI: 0.998–1.001). DISCUSSION The RM did not alter the rates of incidence of peritonitis, mortality, or hospitalization; however, peritonitis episodes occurred later among patients on RM-APD, and dropouts following infection were lower in this group. These findings suggest that RM may alter the clinical course of peritonitis by facilitating earlier diagnosis and more timely intervention. The longer time to the first peritonitis episode observed in the RM-APD group aligns with prior studies 15 , 16 , which reported indirect benefits of RM on treatment continuity and adherence in patients undergoing APD. While no significant differences were noted in subsequent peritonitis episodes, hospitalization, or peritonitis-related mortality, the reduced rate of technique failure indicates a potential role of RM in preserving long-term dialysis viability. From a pathophysiological standpoint, continuous monitoring of ultrafiltration (UF), dwell dynamics, and alert patterns enables the clinical team to detect subtle, early alterations in treatment performance. While no statistically significant association was found between UF trends and treatment response, a consistent decline in UF was noted during peritonitis follow-up. This observation aligns with the findings of Rojas-Díaz and Ramos, who reported similar UF variations preceding peritonitis onset, suggesting that remote monitoring may function as an early warning system 17 . Additionally, it may help identify non-responders sooner, allowing for timely interventions such as antibiotic adjustment, catheter reassessment, or a shift to alternative dialysis modalities 18 . Organizationally, RM represents a transformative opportunity for high-volume healthcare systems such as the Mexican Institute of Social Security (IMSS). Previous reports 10 19 have shown that remote oversight through platforms like Sharesource® reduces the need for in-person consultations, enhances team responsiveness, and improves institutional resource utilization without compromising patient safety 12,15,20 . Additionally, RM may empower patients by providing real-time feedback, potentially improving engagement and self-care. This analysis stems from a cluster randomized controlled trial, a design that inherently carries the risk of inter-center variability. However, no significant differences were observed between groups at the cluster level in patient enrollment rates, suggesting balanced recruitment. Furthermore, patient-level analyses demonstrated consistent trends favoring RM-APD, which reinforces the internal validity of our findings. The relatively small sample size for UF-related analyses may have limited statistical power to detect associations with stronger significance. This study provides evidence that may inform the development of predictive models using data derived from RM in peritoneal dialysis. Previous works have demonstrated the feasibility of applying artificial intelligence to RM data for the early identification of clinical complications such as peritonitis or suboptimal treatment response 21 , 22 . These emerging approaches reflect a growing interest in incorporating RM into clinical decision-making frameworks, aligning with the principles of precision nephrology and anticipatory care. Clinical Implications for Practice The implementation of RM in APD programs offers a scalable, strategic innovation for IMSS. By enabling real-time surveillance, RM facilitates earlier identification of peritonitis, supports prompt clinical decisions, and potentially reduces unnecessary hospitalizations. Objective data provided by RM platforms can improve the efficiency and responsiveness of clinical teams while promoting patient-centered care. Additionally, RM may enhance treatment adherence and reduce technique dropout, ultimately improving long-term clinical outcomes. In high-demand health systems, this translates into more sustainable care models and optimized use of institutional resources. Study Limitations The original cluster design may introduce heterogeneity between participating centers regarding peritonitis incidence. However, patient-level analyses yielded consistent results, reinforcing the reliability of the findings. Moreover, the limited number of patients with complete UF data may have constrained the ability to detect statistically significant trends in treatment response. A second concern is the difference in age distribution between groups; however, it cannot be attributed to inappropriate randomization, as age did not differ in the original study. Advanced age is associated with immunosenescence, which can lead to a diminished response to infection (as lower leucocyte count suggests), slower clinical recovery, an increased risk of technique failure, and a lower skill level in patients from the APD group in the management of PD. Although age was adjusted for in multivariate models, this imbalance may still have influenced the observed outcomes and should be considered when interpreting the results. CONCLUSION While RM-APD does not reduce the overall incidence of peritonitis, it alters the clinical trajectory of these episodes by facilitating continuous treatment monitoring, timely clinical interventions, and sustained technique viability. These results advocate for the integration of RM into institutional dialysis programs. Future studies should focus on developing predictive models using RM data to anticipate adverse events and tailor peritonitis management strategies accordingly. Declarations Ethics approval and consent to participate: This study is a secondary analysis derived from a previously published cluster-randomized controlled trial. It was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of the Medical Research Unit in Nephrological Diseases, IMSS (Reference: R-2021-3601-043). All participants in the original trial provided written informed consent. Consent for publication: Not applicable. Competing interests: The authors declare that they have no competing interests. Sources of funding: This research received financial support from "Baxter Company Research and Continuing Education Groups." Authors’ contributions: J.R.P.S. and M.A.C.B. conceptualized and designed the study. M.A.C.B. conducted the statistical analyses and data interpretation. J.R.P.S., M.A.C.B., and J.C.A. drafted the manuscript. All authors contributed to critical revision and approved the final version of the manuscript. Acknowledgements: The authors thank the staff of the Medical Research Unit in Nephrological Diseases and the patients who participated in the original trial. We extend a special acknowledgment to the workers of the participating hospitals indicated below: Hospital de Especialidades "Dr. Belisario Domínguez", IMSS Hospital General de Zona 194, IMSS Hospital General de Zona 1-A DR. Rodolfo Antonio de Mucha Macías "Venados", IMSS Hospital General De Zona Médico Familiar N° 6, IMSS Hospital General De Zona Médico Familiar N° 8, San Ángel, IMSS Hospital General de Zona N° 194, IMSS Hospital General De Zona N° 2-A, IMSS Hospital General de Zona N° 30, IMSS Hospital General de Zona N° 32, IMSS Hospital General de Zona N° 33, IMSS Hospital General de Zona N° 46, IMSS Hospital General de Zona N° 47, IMSS Hospital General de Zona N° 58, IMSS Hospital General Regional 1 Dr. Carlos Mac Gregor Sánchez Navarro, IMSS Hospital General Regional 180, IMSS Hospital General Regional 251 Metepec, IMSS Hospital General Regional N° 45, IMSS Hospital General Regional N° 66, IMSS Unidad Médica de Atención Ambulatoria (UMAA), IMSS, Hospital General de Zona N° 6, IMSS, Hospital General de Zona N° 89, IMSS. UMAE No. 1, Instituto de Seguridad y Servicios Sociales de los Trabajadores al Servicio de los Poderes del Estado de Puebla. References Mcdonald S, Hurst K. Fiona Brown Aarti Gulyani Chapter 6 Peritoneal Dialysis 2012 Annual Report-35th Edition .; 2012. Boudville N, Kemp A, Clayton P, et al. Recent peritonitis associates with mortality among patients treated with peritoneal dialysis. J Am Soc Nephrol . 2012;23(8):1398-1405. doi:10.1681/ASN.2011121135 Szeto CC, Li PKT. Peritoneal Dialysis-Associated Peritonitis. Clin J Am Soc Nephrol . 2019;14(7):1100-1105. doi:10.2215/CJN.14631218 Li PKT, Szeto CC, Piraino B, et al. ISPD peritonitis recommendations: 2016 update on prevention and treatment. Perit Dial Int . 2016;36(5):481-508. doi:10.3747/pdi.2016.00078 Ahbap E, Mazi EE, Basturk T, Sakaci T, Aykent MB, Unsal A. Peritoneal dialysis related non-infectious complications: A single-center experience over 20 years. Clin Nephrol . 2023;100(1):19-27. doi:10.5414/CN111092 Hepburn KS, Lambert K, Mullan J, McAlister B, Lonergan M, Cheikh Hassan HI. Peritoneal dialysis related peritonitis as a risk factor for cardiovascular events. Intern Med J . Published online February 2020. doi:10.1111/imj.14769 Terri M, Trionfetti F, Montaldo C, et al. Mechanisms of Peritoneal Fibrosis: Focus on Immune Cells–Peritoneal Stroma Interactions. doi:10.3389/fimmu.2021.607204 Polanco E, Aquey M, Collado J, et al. A COVID-19 pandemic-specific, structured care process for peritoneal dialysis patients facilitated by telemedicine: Therapy continuity, prevention, and complications management. Ther Apher Dial . 2021;(October 2020):1-9. doi:10.1111/1744-9987.13635 Cho Y, Johnson DW. Peritoneal dialysis-related peritonitis: towards improving evidence, practices, and outcomes. Am J kidney Dis Off J Natl Kidney Found . 2014;64(2):278-289. doi:10.1053/j.ajkd.2014.02.025 Sanabria M, Buitrago G, Lindholm B, et al. Remote patient monitoring program in automated peritoneal dialysis: Impact on hospitalizations. Perit Dial Int . 2019;39(5):472-478. doi:10.3747/pdi.2018.00287 Bunch A, Vesga JI, Camargo DO, et al. Remote Automated Peritoneal Dialysis Management in Colombia. Kidney Int Reports . 2019;4(6):873. doi:10.1016/J.EKIR.2019.03.017 Cuevas-Budhart MÁ, Villeda MT, Delgado AMC, et al. Remote monitoring as a surveillance method in patients on automated peritoneal dialysis for preventing complications and COVID-19 contagion. J Infect Public Health . Published online July 27, 2023. doi:10.1016/J.JIPH.2023.07.019 Paniagua R, Ramos A, Ávila M, et al. Remote monitoring of automated peritoneal dialysis reduces mortality, adverse events and hospitalizations: a cluster-randomized controlled trial. Nephrol Dial Transplant . 2025;40(3):588-597. doi:10.1093/NDT/GFAE188 Li PKT, Chow KM, Cho Y, et al. ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment. Perit Dial Int . 2022;42(2):110-153. doi:10.1177/08968608221080586/ASSET/F4B5AEDD-F398-4B08-A7A7-C8E506265EAD/ASSETS/IMAGES/LARGE/10.1177_08968608221080586-FIG10.JPG Milan Manani S, Baretta M, Giuliani A, et al. Remote monitoring in peritoneal dialysis: benefits on clinical outcomes and on quality of life. J Nephrol . 2020;33(6):1301-1308. doi:10.1007/s40620-020-00812-2 Centellas-Pérez FJ, Ortega-Cerrato A, Vera M, et al. Impact of Remote Monitoring on Standardized Outcomes in Nephrology-Peritoneal Dialysis. Kidney Int reports . 2023;9(2):266-276. doi:10.1016/J.EKIR.2023.10.034 Rojas-Diaz M, Ramos A. Help of Remote Patient Monitoring in the Assessment of Changes in Ultrafiltration before, during, and after a Peritonitis Episode in Patients on Automated Peritoneal Dialysis. November 2017. Accessed April 21, 2025. https://www.asn-online.org/education/kidneyweek/2017/program-abstract.aspx?controlId=2784136 Praha N, Sriyuktasuth A, Puwarawuttipanit W, Chuengsaman P, Kusakunniran W. Factors Influencing Telehealth Service Use and Health Outcomes in Patients Undergoing Continuous Ambulatory Peritoneal Dialysis: Cross-Sectional Study. J Med Internet Res . 2023;25:e48623. doi:10.2196/48623 Paniagua R, Ramos A, Ávila M, et al. Remote monitoring of automated peritoneal dialysis reduces mortality, adverse events, and hospitalizations: a cluster randomized controlled trial. Nephrol Dial Transplant . Published online August 20, 2024. doi:10.1093/NDT/GFAE188 Paniagua R, Ávila-Díaz M, Trejo-Villeda MÁ, Bernal-Amador AS, Ramos A. Utility of remote monitoring in patients on automated peritoneal dialysis. Rev Invest Clin . 2023;75(6):318-326. doi:10.24875/RIC.23000206 Ruiz IAG. Experience with Remote Monitoring of Automated Peritoneal Dialysis: The First 50 Patients in a Private Peritoneal Dialysis Program in Mexico. J Am Soc Nephrol . 2023;34(11S):181-181. doi:10.1681/ASN.20233411S1181B Ma L, Zhang C, Gao J, et al. Mortality prediction with adaptive feature importance recalibration for peritoneal dialysis patients. Patterns . 2023;4(12):100892. doi:10.1016/J.PATTER.2023.100892 Tables Table 1. Characteristics of the population by group Variable Total APD RM-APD n=95 n X±SD n X±SD n X±SD p-value Age 95 47.58 ± 16.26 48 52.66 ± 14.76 47 42.39 ± 16.23 .002 Gender f (%) 48 47 Male 69 (71.6) 37 (77.1) 31 (66.0) .229 Female 27 (28.4) 11 (22.9) 16 (34.0) Occupation 93 46 47 Employed 3 1(32.6) 16 (34.8) 15 (31.9) .698 None 20 (21.1) 11 (23.4) 9 (19.1) Home 14 (14.7) 6 (13.0) 8 (17.0) Own business 8 (8.4) 4 (8.7) 4 (8.2) Laborer 3 (3.2) 2 (4.3) 1 (2.1) Student 3 (3.2) 3 (6.4) Other 14 (14.7) 7 (15.2) 7 (14.9) Marital status 94 47 47 Married 56 (58.9) 32 (68.1) 24 (51.1) .228 Single 22 (23.2) 19 (19.1) 13 (27.7) Free union 7 (7.4) 1 (2.1) 6 (12.8) Widow 5 (5.3) 3 (6.4) 2 (4.3) Divorced 4 (4.2) 2 (4.3) 2 (4.3) Academic level 92 45 47 None 2 (2.1) 1 (2.2) 1 (2.1) .802 Primary 22 (23.2) 11 (24.4) 11 (23.4) Secondary 29 (30.5) 15 (33.3) 14 (29.8) High school 23 (24.2) 10 (22.2) 13 (27.7) Vocational 6 (6.3) 4 (8.7) 2 (4.3) Professional 8 (8.3) 4 (8.7) 4 (8.5) Postgraduate 2 (2.1) 0 2 (4.3) Monthly Family Income (MXN) 91 45 46 Less than $2,650 12 (12.6) 4 (8.9) 8 (17.4) .335 $2,651 - $5,301 34 (35.8) 14 (31.1) 20 (43.5) $5,302 - $7,952 27 (28.4) 16 (35.6) 11 (23.9) $7,953 - $10,603 13 (13.7 7 (15.6) 6 (13.0) $10,604 - $13,254 3 (3.2) 2 (4.4) 1 (2.2) More than $13,154 2 (2.1) 2 (4.4) Self-sufficiency 90 47 43 Yes 64 (67.4) 30 (63.8) 34 (79.1) .111 No 26 (27.4) 17 (36.2) 9 (19.1) Catheter type 92 45 47 Straight Cuffed 3 (3.2) 0 3 (6.4) .085 Pig-Tail Cuffed 90 (96.8) 45 (100) 44 (93.6) *Renal tuberculosis, preeclampsia, erythematous lupus, renal lithiasis, hypoplasia, eclampsia, renal agenesia, nephrectomy. Table 2. Clinical Characteristics and Laboratory Values by Result Total ADP RM-APD P- V N n n Temperature (ºC) 95 36.33 ± 0.31 48 36.36 ± 0.33 47 36.29 ± 0.28 0.23 Heart rate (bpm) 93 80.43 ±9.37 46 79.93 ± 9.23 47 80.91 ± 9.58 0.38 Systolic blood pressure (mmHg) 94 133.65 ±19.74 48 135.73 ± 19.11 46 131.48 ± 20.36 0.62 Diastolic blood pressure (mmHg) 93 80.22 ±11.27 47 80.79 ± 9.46 46 79.63 ± 12.95 0.06 Weight (kg) 94 72.56 ±13.76 47 72.77 ± 14.02 47 72.35 ±13.65 0.35 Height (m) 92 164.29 ±8.36 47 163.85 ± 7.78 45 164.76 ±9.00 0.13 Hemoglobin (g/dL) 75 10.97 ±6.92 33 10.03 ± 2.18 42 11.71±9.03 0.24 Hematocrit (%) 84 27.42±10.07 40 25.86 ± 10.93 44 28.84±9.13 0.09 Leukocytes (cells/mm3) 84 8717.05±13960.44 41 4956.60±4048.91 43 12302.61±18508.58 0.39 Lymphocytes (Cells/mm3) 72 3961.62±6185.42 40 3243.73±5059.37 32 4859.00±7343.50 0.47 Neutrophils (Cells/mm3) 70 10088.13± 18754.02 38 5450.78±10478.46 32 15594.98± 24374.81 0.02 Platelet count (Cells/mcL) 72 291.99±267.55 33 338.06±76.05 39 253.01±86.46 0.10 Serum Glucose (mg/dL) 78 129.72±82.18 37 116.19±43.02 41 141.94±35.24 0.39 Serum Creatinine (mg/24hrs) 86 25.56±39.15 41 30.03±80.12 45 21.49±79.24 0.08 Serum Urea (mg/dL) 88 122.19±79.92 43 111.39±48.79 45 132.53±41.37 1.00 BUN (mg/dL) 67 77.33±45.29 37 77.79±4.67 30 76.78±6.13 0.57 Serum Sodium (mEq/L) 65 135.94±5.42 32 135.66±19.34 33 136.21±32.26 0.58 Serum Potassium (mEp/L) 71 9.44±26.50 35 9.01±37.43 36 9.87±32.65 0.74 Serum Chloride (mEp/L) 74 86.27±34.79 34 83.35±31.58 40 88.76±31.02 0.25 Serum total Calcium (mg/dL) 61 20.33±31.04 30 20.46±3.49 31 20.22±7.88 0.90 Phosphorous (mg/dL) 61 6.69±6.02 31 6.33±2.18 30 7.08±9.03 0.24 Table 3. Peritonitis rates by group. ADP RM-APD All peritonitis in the studied population* 120 54 65 Peritonitis rate* 0.17 0.19 0.15 First peritonitis 95 48 47 Firs peritonitis rate 0.12 0.12 0.11 Event/100 patients∙year 12 12 11 Follow-up months/patient 102.06 97.59 106.77 Second peritonitis 17 9 8 Event/100 patients∙year 2.00 1.90 1.40 Third Peritonitis 8 7 1 Event/100 patients∙year 0.9 1.8 0.2 Hospitalized 55 29 26 Event/100 patients∙year 6.38 7.43 6.22 Dropout 35 19 16 Event/100 patients∙year 4.33 4.70 3.68 *Original study from Paniagua R et al. 19 Table 4. Comparison of clinical outcomes between therapy remote monitoring APD and Conventional APD n TOTAL n ∑ APD ∑ n RM-APD ∑ p-v Total , Programmed Volume (ml) 75 10,300 ± 1,508 34 10,338 ± 1,636 41 10,268 ± 1,414 0.37 Prescribed Cycles 75 4.45 ± 0.57 34 4.47 ± 0.56 41 4.44 ± 0.59 0.65 Programmed Infusion Volume (ml) 75 2,066 ± 194.05 34 2,038 ± 208.91 41 2,090 ± 180.00 0.46 The last Prescribed Infusion Volume (ml) 49 1,580 ± 614.81 26 1,525 ± 668.02 23 1,643 ± 556.63 0.44 Actual Cycles 75 4.35 ± 0.59 34 4.38 ± 0.58 41 4.33 ± 0.61 0.80 Night dwell Volume (ml) 75 2,022 ± 308.81 34 1,956 ± 4009.27 41 2,076 ± 177.75 0.40 Wet day Infusion Volume (ml) 49 1,544 ± 599.91 26 1481.56 ± 647.35 23 1615.85 ± 546.83 0.50 Initial Drain Volume (ml) 75 818.50 ± 732.73 34 903.74 ± 631.73 41 747.82 ± 807.91 0.26 Actual Overnight Ultrafiltration (ML) 75 655.11 ± 392.35 34 754.48 ± 387.88 41 572.71 ± 381.20 0.81 Actual Total Ultrafiltration (ml) 45 415.01 ± 512.13 25 409.77 ± 553.97 20 421.56 ± 468.69 0.15 Yellow Flags 73 7.47 ± 7.01 34 545 7.79 ± 8.38 265 39 7.18 ± 5.68 280 0.75 Events During Treatment (Number) 53 3.89 ± 4.23 25 206 3.80 ± 4.31 95 28 3.96 ± 4.23 111 0.09 Events during treatment (sum) 53 24.77 ± 28.07 25 1313 24.44 ± 28.99 611 28 25.07 ±27.75 702 0.06 Red Flags 69 13.86 ± 11.50 31 956 14.19 ± 11.57 440 38 13.58 ± 11.59 516 0.64 Events during treatment (number) 31 2.61 ± 2.67 14 81 2.79 ± 3.64 39 17 2.47 ± 1.59 42 0.66 Events during treatment (sum) 31 50.94 ± 78.20 14 1579 65.07 ± 112.04 911 17 39.29 ± 30.76 668 0.73 Alarms 75 63.16 ± 67.27 34 4737 68.76 ± 67.11 2338 41 58.51 ± 45.40 2399 0.19 Days of connection 75 25.53 ± 6.23 34 1915 24.50 ± 6.84 833 41 26.39 ± 5.16 1082 0.45 Additional Declarations No competing interests reported. Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-6993883","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":515985746,"identity":"11bbaf45-c29b-4c72-8595-39fa9202b79f","order_by":0,"name":"Miguel Angel Cuevas-Budhart","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAABC0lEQVRIiWNgGAWjYDACZhBRAONVSEBoxgZCWgxgvDPEaGFA1sLYBmPg0aLbzn5N4oMBg7zB8R7Djz/nWUTL9x9gfvFxB0O0wQHsWswO85RJzjBgMNxw5oyxNO82idwNNxLYLGeeYcidicMmoJY0aR4DhgSDG2kJ0owgLRIMbMa8bQy5/TgcBtbyB6Tl/rPknz/nSOTO7z8A0dKGUwv7MWkGsC3MxyR4GyRyGw4kMD8mYAuzZY+BhOHMM8nHrHmOgfyS2MY484wEbr+cP/7wxo8KG3m+4webb/6oqQM67PDhDx932ORuwBFiDAw8oEiRQBZhbJNAE0ED7A8whJg/4FE/CkbBKBgFIw8AADMDWx06IOsSAAAAAElFTkSuQmCC","orcid":"","institution":"XXI Century National Medical Center, Instituto Mexicano del Seguro Social (IMSS)","correspondingAuthor":true,"prefix":"","firstName":"Miguel","middleName":"Angel","lastName":"Cuevas-Budhart","suffix":""},{"id":515985748,"identity":"a3e5a47e-894a-41ea-b410-96347837b874","order_by":1,"name":"Miguel Angel Trejo-Villeda","email":"","orcid":"","institution":"XXI Century National Medical Center, Instituto Mexicano del Seguro Social (IMSS)","correspondingAuthor":false,"prefix":"","firstName":"Miguel","middleName":"Angel","lastName":"Trejo-Villeda","suffix":""},{"id":515985750,"identity":"d03bac55-4f07-4219-93ce-283803ca2fc3","order_by":2,"name":"Marcela Avila Díaz","email":"","orcid":"","institution":"XXI Century National Medical Center, Instituto Mexicano del Seguro Social (IMSS)","correspondingAuthor":false,"prefix":"","firstName":"Marcela","middleName":"Avila","lastName":"Díaz","suffix":""},{"id":515985751,"identity":"fc57f5fc-4ddb-4831-8c66-48e9a49ec665","order_by":3,"name":"Juan Carlos Enriquez","email":"","orcid":"","institution":"Baxter Healthcare Corporation","correspondingAuthor":false,"prefix":"","firstName":"Juan","middleName":"Carlos","lastName":"Enriquez","suffix":""},{"id":515985753,"identity":"c9d3fc7d-ad57-4dfb-b4d8-58c46c22c661","order_by":4,"name":"Julian Candelario-Lopez","email":"","orcid":"","institution":"Universidad Nacional Autónoma de México","correspondingAuthor":false,"prefix":"","firstName":"Julian","middleName":"","lastName":"Candelario-Lopez","suffix":""},{"id":515985754,"identity":"51229a8f-6b25-40e5-9aa2-ba9d8d21635c","order_by":5,"name":"Alfonso Ramos-Sanchez","email":"","orcid":"","institution":"Macrotech Dominican Republic. Santo Domingo","correspondingAuthor":false,"prefix":"","firstName":"Alfonso","middleName":"","lastName":"Ramos-Sanchez","suffix":""},{"id":515985756,"identity":"f5161e04-6b8e-4868-8e3a-51cadaa54e50","order_by":6,"name":"Ramon Paniagua","email":"","orcid":"","institution":"XXI Century National Medical Center, Instituto Mexicano del Seguro Social (IMSS)","correspondingAuthor":false,"prefix":"","firstName":"Ramon","middleName":"","lastName":"Paniagua","suffix":""}],"badges":[],"createdAt":"2025-06-27 18:38:06","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-6993883/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-6993883/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":91827227,"identity":"5849394c-9d8c-43bd-9122-d45e5ba5e9c7","added_by":"auto","created_at":"2025-09-22 08:46:10","extension":"docx","order_by":0,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":175962,"visible":true,"origin":"","legend":"","description":"","filename":"MainManuscriptPeritonitis010725.docx","url":"https://assets-eu.researchsquare.com/files/rs-6993883/v1/b8ebb534c9a3a9e35d2145d7.docx"},{"id":91828925,"identity":"75519130-c1c4-4d9d-934f-14e2969db82a","added_by":"auto","created_at":"2025-09-22 08:54:11","extension":"json","order_by":1,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":9654,"visible":true,"origin":"","legend":"","description":"","filename":"c75b4bb0590d491f9b3236597d775c56.json","url":"https://assets-eu.researchsquare.com/files/rs-6993883/v1/0079af23df3920d36c858fbe.json"},{"id":91827231,"identity":"182d29ab-3b96-405c-83a9-30e6b153305a","added_by":"auto","created_at":"2025-09-22 08:46:11","extension":"xml","order_by":2,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":127266,"visible":true,"origin":"","legend":"","description":"","filename":"c75b4bb0590d491f9b3236597d775c561enriched.xml","url":"https://assets-eu.researchsquare.com/files/rs-6993883/v1/57a9a0199c5d7380be89f81c.xml"},{"id":91827235,"identity":"4ff3929b-9420-4b43-9b73-a7e99eaeeed6","added_by":"auto","created_at":"2025-09-22 08:46:11","extension":"jpeg","order_by":3,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":516253,"visible":true,"origin":"","legend":"","description":"","filename":"floatimage1.jpeg","url":"https://assets-eu.researchsquare.com/files/rs-6993883/v1/85c993f9dcae334256501de7.jpeg"},{"id":91828922,"identity":"5ee18962-5ca3-4281-bb03-b386a1e20e8d","added_by":"auto","created_at":"2025-09-22 08:54:10","extension":"png","order_by":4,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":13918,"visible":true,"origin":"","legend":"","description":"","filename":"floatimage2.png","url":"https://assets-eu.researchsquare.com/files/rs-6993883/v1/f04a4e48f5f1d4cfbf7e1587.png"},{"id":91827233,"identity":"38ca3062-dd4d-4845-98cb-037d21d9d1de","added_by":"auto","created_at":"2025-09-22 08:46:11","extension":"png","order_by":5,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":21966,"visible":true,"origin":"","legend":"","description":"","filename":"floatimage3.png","url":"https://assets-eu.researchsquare.com/files/rs-6993883/v1/1732414384b23900b25e9af7.png"},{"id":91827230,"identity":"31108876-b564-4dd7-8d22-feea6bba3141","added_by":"auto","created_at":"2025-09-22 08:46:11","extension":"png","order_by":6,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":21087,"visible":true,"origin":"","legend":"","description":"","filename":"floatimage4.png","url":"https://assets-eu.researchsquare.com/files/rs-6993883/v1/82e2a09ab016306f7a144e7b.png"},{"id":91827239,"identity":"03a27139-1f28-4474-b3c5-3effcdb3d598","added_by":"auto","created_at":"2025-09-22 08:46:11","extension":"png","order_by":7,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":112164,"visible":true,"origin":"","legend":"","description":"","filename":"Onlinefloatimage1.png","url":"https://assets-eu.researchsquare.com/files/rs-6993883/v1/a2970a986f5c6c6b61a16e09.png"},{"id":91827237,"identity":"fd836363-ff9b-499b-ba4a-7d2e409cd790","added_by":"auto","created_at":"2025-09-22 08:46:11","extension":"png","order_by":8,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":7544,"visible":true,"origin":"","legend":"","description":"","filename":"Onlinefloatimage2.png","url":"https://assets-eu.researchsquare.com/files/rs-6993883/v1/2637df72b66d2bb1c179e27a.png"},{"id":91828927,"identity":"e423bf7c-619d-444f-8f5d-a4fabde60be1","added_by":"auto","created_at":"2025-09-22 08:54:11","extension":"png","order_by":9,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":9571,"visible":true,"origin":"","legend":"","description":"","filename":"Onlinefloatimage3.png","url":"https://assets-eu.researchsquare.com/files/rs-6993883/v1/78543e061a7385cc93332f61.png"},{"id":91827241,"identity":"79b91d85-c1a2-4529-a956-c0801213a4b6","added_by":"auto","created_at":"2025-09-22 08:46:11","extension":"png","order_by":10,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":9091,"visible":true,"origin":"","legend":"","description":"","filename":"Onlinefloatimage4.png","url":"https://assets-eu.researchsquare.com/files/rs-6993883/v1/a39ff2f19efec03476f4ea4c.png"},{"id":91828931,"identity":"b94f9d79-5d50-4531-9df4-8f6e988f6d0f","added_by":"auto","created_at":"2025-09-22 08:54:11","extension":"xml","order_by":11,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":124826,"visible":true,"origin":"","legend":"","description":"","filename":"c75b4bb0590d491f9b3236597d775c561structuring.xml","url":"https://assets-eu.researchsquare.com/files/rs-6993883/v1/efd0166640e637fa786b5d27.xml"},{"id":91827242,"identity":"28183c18-28df-48fa-abdf-2333dc7e5f0b","added_by":"auto","created_at":"2025-09-22 08:46:11","extension":"html","order_by":12,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":135198,"visible":true,"origin":"","legend":"","description":"","filename":"earlyproof.html","url":"https://assets-eu.researchsquare.com/files/rs-6993883/v1/cd402a7419b21b019ae1175b.html"},{"id":91827225,"identity":"bf803513-8fb9-4a3b-9502-07a9a08cb169","added_by":"auto","created_at":"2025-09-22 08:46:10","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":67798,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eCONSORT flowchart of patient selection, allocation, and follow-up.\u003c/strong\u003e\u003c/p\u003e","description":"","filename":"1.png","url":"https://assets-eu.researchsquare.com/files/rs-6993883/v1/5ea860de9e0a2845dd7e972b.png"},{"id":91827226,"identity":"d87624b3-9651-4cae-a0f3-b87865265fff","added_by":"auto","created_at":"2025-09-22 08:46:10","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":62271,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eDays of follow-up until first Peritonitis\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eCumulative risk of first peritonitis. Median time to first episode: 14.81 months in the RM-APD group and 11.20 months in the APD group (p \u0026lt; 0.001).\u003c/p\u003e","description":"","filename":"2.png","url":"https://assets-eu.researchsquare.com/files/rs-6993883/v1/0c083f7496a9155569bbd3fa.png"},{"id":91828921,"identity":"4679dd70-144e-403c-b5d8-2230d002000c","added_by":"auto","created_at":"2025-09-22 08:54:10","extension":"png","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":97194,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eCumulative risk of hospitalization for peritonitis by treatment group\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe cumulative risk of hospitalization for peritonitis was significantly lower in the RM-APD group: 19.65 months, APD group: 18.00 months (p = 0.003).\u003c/p\u003e","description":"","filename":"3.png","url":"https://assets-eu.researchsquare.com/files/rs-6993883/v1/5f0dfa8c52f68f38d02f6678.png"},{"id":91828924,"identity":"abc17f71-663a-4b6c-91c0-5bddb5a6d40c","added_by":"auto","created_at":"2025-09-22 08:54:11","extension":"png","order_by":4,"title":"Figure 4","display":"","copyAsset":false,"role":"figure","size":105164,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eCumulative risk of technique dropout due to peritonitis by treatment group\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eCumulative risk of temporary or definitive dropout due to peritonitis. Median time to dropout was 19.80 months in the RM-APD group and 18.24 months in the APD group (p = 0.001).\u003c/p\u003e","description":"","filename":"4.png","url":"https://assets-eu.researchsquare.com/files/rs-6993883/v1/3196224657d80ea42887dd86.png"},{"id":92109091,"identity":"03c422f2-73d8-4cf0-b30c-03f09e022cad","added_by":"auto","created_at":"2025-09-24 17:46:40","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":1551297,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-6993883/v1/16507592-5b01-4395-9312-778fa4a5a11f.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"Remote Monitoring in Automated Peritoneal Dialysis Modifies the Clinical Course of Peritonitis: A Secondary Analysis of a Cluster Randomized Trial","fulltext":[{"header":"INTRODUCTION","content":"\u003cp\u003eInfectious peritonitis is the most common complication in patients undergoing Peritoneal Dialysis (PD). It is the direct cause of death in \u0026gt;15% of PD deceased patients and the cause of approximately 16-20% of PD technique failure\u003csup\u003e1\u0026ndash;3\u003c/sup\u003e. Peritonitis induces structural and functional damage in the peritoneal membrane even after a single episode, and severe or repeated infections can lead to membrane failure expressed by ultrafiltration (UF) failure\u003csup\u003e4,5\u003c/sup\u003e. Peritonitis has been a risk factor for mortality for a long time since it is an inductor of systemic inflammation and fluid overload secondary to derangement of UF, both associated with cardiovascular events\u003csup\u003e6,7\u003c/sup\u003e.\u003c/p\u003e\n\u003cp\u003ePeritonitis rates vary widely, even up to 20 times, depending on non-modifiable factors such as age, diabetes and other comorbidities, education, and economic levels. Modifiable factors, such as the size of the dialysis program and attending population, staff training, and the success of the training programs for patients or their caregivers, also influence peritonitis rates\u003csup\u003e8\u003c/sup\u003e\u003csup\u003e,\u003c/sup\u003e\u003csup\u003e9\u003c/sup\u003e.\u003c/p\u003e\n\u003cp\u003eRemote monitoring (RM), a recent advance in PD technology, allows the PD team to have closer surveillance of the patients; it allows the follow-up of prescribed treatment, as well as effective dialysis time, UF volume, inflow and drain of PD solutions patterns and patient\u0026rsquo;s skill in the management of the device. This information enables the early detection of clinically relevant issues, such as catheter permeability, peritonitis, treatment adherence, and UF problems. The correct use of this information enables the establishment of proactive actions that can decrease adverse events and hospitalizations\u0026nbsp;\u003csup\u003e8\u003c/sup\u003e\u003csup\u003e,\u003c/sup\u003e \u003csup\u003e10\u0026ndash;12\u003c/sup\u003e.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eThe objective of this study was to evaluate the utility of remote monitoring in the clinical follow-up of peritonitis episodes in patients undergoing automated peritoneal dialysis by comparing clinical outcomes, ultrafiltration trends, and treatment response between those managed with or without remote monitoring.\u003c/p\u003e"},{"header":"METHODOLOGY","content":"\u003cp\u003eA secondary study was conducted among patients who participated in a cluster-randomized clinical trial \u003csup\u003e13\u003c/sup\u003e comparing Remote Monitoring of Automated Peritoneal Dialysis (RM-APD) with conventional Automated Peritoneal Dialysis (APD). The protocol of the original study was approved by the National Commission of Scientific Research and the local Research Committees of each hospital. Data from patients with a diagnosis of infectious peritonitis during the peritonitis phase (from 2018 to April 2020) were extracted from the central database of the two arms of the original study. \u0026nbsp;\u003c/p\u003e\n\u003cp\u003eThe extracted information contains data on socio-demographic characteristics, baseline clinical data, as well as records of comorbidities and adverse events. The devices used in the original study were Homechoice Claria\u0026reg;, Baxter, S.A. de C.V., equipped with a device for RM (Sharesource\u0026reg; connectivity platform, Baxter Healthcare, Deerfield, IL, USA).\u003c/p\u003e\n\u003cp\u003eSelected patients met the diagnostic criteria of peritonitis according to the ISPD, which include characteristic clinical data, such as abdominal pain, cloudy dialysis effluent, \u003csup\u003e3,14\u003c/sup\u003e leukocyte counts in dialysis effluent \u0026gt;100/\u0026micro;l (with a minimum permanence of 2 hours), \u0026gt;50% polymorph nuclear cells, and positive effluent culture \u003csup\u003e4\u003c/sup\u003e. The antibiotic prescription was based on the recommendations of the ISPD Clinical Guidelines. \u0026nbsp;\u003c/p\u003e\n\u003cp\u003eTo evaluate the impact of peritonitis on ultrafiltration (UF), the date of clinical diagnosis was defined as the reference point. UF data were extracted from the Sharesource\u0026reg; platform over a 30-day post-diagnosis period. UF patterns were compared between patients who achieved clinical resolution and those who did not respond to antibiotic therapy.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eStatistical analysis\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eQualitative variables are expressed as simple frequencies and percentages. Quantitative continuous variables are expressed through their mean and standard deviation. Differences between groups were analyzed by Student\u0026acute;s \u0026ldquo;t\u0026rdquo; test or Squared Chi test according variable characteristics.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eTo assess the effect of RM-APD on peritonitis episodes, incidence rates were analyzed at both the cluster and patient levels. Time-to-event outcomes, including time to first peritonitis episode, first hospitalization, and death, were evaluated using Kaplan\u0026ndash;Meier survival curves and compared with the log-rank test. Multivariable Cox proportional hazards models were used to adjust for potential confounders, with results reported as hazard ratios (HR) and 95% confidence intervals (CI).\u003c/p\u003e\n\u003cp\u003eUF dynamics during peritonitis episodes were analyzed using data extracted from the Sharesource\u0026reg; platform. Comparisons were made between patients who responded to antibiotic therapy and those who did not, as well as between patients with and without catheter dysfunction. Additional analyses included treatment adherence and the amount of dialysis time lost during the episode.\u003c/p\u003e"},{"header":"RESULTS","content":"\u003cp\u003eIn the original study, 801 patients were enrolled: 398 in the APD group and 403 in the RM-APD group. Baseline clinical and biochemical characteristics were similar between groups. Figure 1 shows the patient selection and follow-up process. A total of 95 patients developed peritonitis and were included in the analysis.\u003c/p\u003e\n\u003cp\u003eFollow-up continued until clinical recovery was achieved or, in the event of management needs, leave from the study was recommended. Several patients in the conventional APD group were shifted to CAPD to optimize antibiotic management, which limited the availability of Sharesource data for some cases. There were no significant differences between groups in the number of peritonitis episodes or their incidence rates.\u003c/p\u003e\n\u003cp\u003eTable 1 presents the socio-demographic data for all patients with peritonitis and divided by study group. Except for age, there was no difference. The RM-APD group was ten years younger than the APD group. Table 2 presents the clinical parameters of both groups analyzed (APD and RM-APD). Most variables showed no difference except for neutrophils.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eThe time (in months) from baseline until the first episode of peritonitis was significantly longer in the RM-APD group (14.81 months) compared to the APD group (11.20 months) (p \u0026lt;0.001), as shown in Figure 2. During the follow-up period, there were no differences between groups in the rates of first and subsequent peritonitis, hospitalization rates or days of hospitalization for peritonitis, or deaths secondary to peritonitis (Table 3).\u003c/p\u003e\n\u003cp\u003eHowever, patient-level analyses revealed that the time from baseline to first hospitalization for peritonitis (p = 0.003) and dropout due to peritonitis (p = 0.001) were significantly shorter in the APD group, as shown in Figures 3 and 4, respectively.\u003c/p\u003e\n\u003cp\u003eThe data provided by the Sharesource platform is shown in Table 4. There were no significant differences between the groups. No relationship was found between episodes of peritonitis and exit site infections or tunnel infections, nor between peritonitis and mechanical problems with the catheter. No statistical significance was found regarding the variation of UF data provided by the Sharesource platform (\u0026beta;: 0.999; 95% CI: 0.998-1.001) during and after recovery from peritonitis.\u003c/p\u003e\n\u003cp\u003eFinally, for the logistic regression analysis of factors associated with peritonitis recovery, no statistically significant associations were found. Factors include empirical monotherapy (\u0026beta; = 2.571; 95% CI: 0.721\u0026ndash;9.167), empirical therapy covering both Gram-positive and Gram-negative bacteria (\u0026beta; = 0.400; 95% CI: 0.040\u0026ndash;3.955), and targeted therapy (\u0026beta; = 0.727; 95% CI: 0.258\u0026ndash;2.053). Additionally, ultrafiltration data from the Sharesource\u0026reg; platform showed no significant association (\u0026beta; = 0.999; 95% CI: 0.998\u0026ndash;1.001).\u003c/p\u003e"},{"header":"DISCUSSION","content":"\u003cp\u003eThe RM did not alter the rates of incidence of peritonitis, mortality, or hospitalization; however, peritonitis episodes occurred later among patients on RM-APD, and dropouts following infection were lower in this group. These findings suggest that RM may alter the clinical course of peritonitis by facilitating earlier diagnosis and more timely intervention.\u003c/p\u003e\n\u003cp\u003eThe longer time to the first peritonitis episode observed in the RM-APD group aligns with prior studies\u0026nbsp;\u003csup\u003e15\u003c/sup\u003e,\u003csup\u003e16\u003c/sup\u003e, which reported indirect benefits of RM on treatment continuity and adherence in patients undergoing APD. While no significant differences were noted in subsequent peritonitis episodes, hospitalization, or peritonitis-related mortality, the reduced rate of technique failure indicates a potential role of RM in preserving long-term dialysis viability.\u003c/p\u003e\n\u003cp\u003eFrom a pathophysiological standpoint, continuous monitoring of ultrafiltration (UF), dwell dynamics, and alert patterns enables the clinical team to detect subtle, early alterations in treatment performance. While no statistically significant association was found between UF trends and treatment response, a consistent decline in UF was noted during peritonitis follow-up. This observation aligns with the findings of Rojas-D\u0026iacute;az and Ramos, who reported similar UF variations preceding peritonitis onset, suggesting that remote monitoring may function as an early warning system\u003csup\u003e17\u003c/sup\u003e. Additionally, it may help identify non-responders sooner, allowing for timely interventions such as antibiotic adjustment, catheter reassessment, or a shift to alternative dialysis modalities\u003cstrong\u003e\u003csup\u003e18\u003c/sup\u003e\u003c/strong\u003e\u003cstrong\u003e.\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eOrganizationally, RM represents a transformative opportunity for high-volume healthcare systems such as the Mexican Institute of Social Security (IMSS). Previous reports \u003csup\u003e10\u003c/sup\u003e \u003csup\u003e19\u003c/sup\u003e have shown that remote oversight through platforms like Sharesource\u0026reg; reduces the need for in-person consultations, enhances team responsiveness, and improves institutional resource utilization without compromising patient safety\u003csup\u003e12,15,20\u003c/sup\u003e. Additionally, RM may empower patients by providing real-time feedback, potentially improving engagement and self-care.\u003c/p\u003e\n\u003cp\u003eThis analysis stems from a cluster randomized controlled trial, a design that inherently carries the risk of inter-center variability. However, no significant differences were observed between groups at the cluster level in patient enrollment rates, suggesting balanced recruitment. Furthermore, patient-level analyses demonstrated consistent trends favoring RM-APD, which reinforces the internal validity of our findings. The relatively small sample size for UF-related analyses may have limited statistical power to detect associations with stronger significance.\u003c/p\u003e\n\u003cp\u003eThis study provides evidence that may inform the development of predictive models using data derived from RM in peritoneal dialysis. Previous works have demonstrated the feasibility of applying artificial intelligence to RM data for the early identification of clinical complications such as peritonitis or suboptimal treatment response\u003csup\u003e21\u003c/sup\u003e\u003csup\u003e,\u003c/sup\u003e\u003csup\u003e22\u003c/sup\u003e. These emerging approaches reflect a growing interest in incorporating RM into clinical decision-making frameworks, aligning with the principles of precision nephrology and anticipatory care.\u003c/p\u003e\n\u003cp\u003eClinical Implications for Practice\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eThe implementation of RM in APD programs offers a scalable, strategic innovation for IMSS. By enabling real-time surveillance, RM facilitates earlier identification of peritonitis, supports prompt clinical decisions, and potentially reduces unnecessary hospitalizations. Objective data provided by RM platforms can improve the efficiency and responsiveness of clinical teams while promoting patient-centered care.\u003c/p\u003e\n\u003cp\u003eAdditionally, RM may enhance treatment adherence and reduce technique dropout, ultimately improving long-term clinical outcomes. In high-demand health systems, this translates into more sustainable care models and optimized use of institutional resources.\u003c/p\u003e\n\u003cp\u003eStudy Limitations\u003c/p\u003e\n\u003cp\u003eThe original cluster design may introduce heterogeneity between participating centers regarding peritonitis incidence. However, patient-level analyses yielded consistent results, reinforcing the reliability of the findings. Moreover, the limited number of patients with complete UF data may have constrained the ability to detect statistically significant trends in treatment response.\u003c/p\u003e\n\u003cp\u003eA second concern is the difference in age distribution between groups; however, it cannot be attributed to inappropriate randomization, as age did not differ in the original study. Advanced age is associated with immunosenescence, which can lead to a diminished response to infection (as lower leucocyte count suggests), slower clinical recovery, an increased risk of technique failure, and a lower skill level in patients from the APD group in the management of PD. Although age was adjusted for in multivariate models, this imbalance may still have influenced the observed outcomes and should be considered when interpreting the results.\u003c/p\u003e"},{"header":"CONCLUSION","content":"\u003cp\u003eWhile RM-APD does not reduce the overall incidence of peritonitis, it alters the clinical trajectory of these episodes by facilitating continuous treatment monitoring, timely clinical interventions, and sustained technique viability. These results advocate for the integration of RM into institutional dialysis programs. Future studies should focus on developing predictive models using RM data to anticipate adverse events and tailor peritonitis management strategies accordingly.\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eEthics approval and consent to participate:\u003c/strong\u003e This study is a secondary analysis derived from a previously published cluster-randomized controlled trial. It was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of the Medical Research Unit in Nephrological Diseases, IMSS (Reference: R-2021-3601-043). All participants in the original trial provided written informed consent.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConsent for publication:\u003c/strong\u003e Not applicable.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompeting interests:\u003c/strong\u003e The authors declare that they have no competing interests.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eSources of funding:\u003c/strong\u003e This research received financial support from \u0026quot;Baxter Company Research and Continuing Education Groups.\u0026quot;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors\u0026rsquo; contributions:\u003c/strong\u003e J.R.P.S. and M.A.C.B. conceptualized and designed the study. M.A.C.B. conducted the statistical analyses and data interpretation. J.R.P.S., M.A.C.B., and J.C.A. drafted the manuscript. All authors contributed to critical revision and approved the final version of the manuscript.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAcknowledgements:\u0026nbsp;\u003c/strong\u003eThe authors thank the staff of the Medical Research Unit in Nephrological Diseases and the patients who participated in the original trial.\u003c/p\u003e\n\u003cp\u003eWe extend a special acknowledgment to the workers of the participating hospitals indicated below: Hospital de Especialidades \u0026quot;Dr. Belisario Dom\u0026iacute;nguez\u0026quot;, IMSS Hospital General de Zona 194, IMSS Hospital General de Zona 1-A DR. Rodolfo Antonio de Mucha Mac\u0026iacute;as \u0026quot;Venados\u0026quot;, IMSS Hospital General De Zona M\u0026eacute;dico Familiar N\u0026deg; 6, IMSS Hospital General De Zona M\u0026eacute;dico Familiar N\u0026deg; 8, San \u0026Aacute;ngel, IMSS Hospital General de Zona N\u0026deg; 194, IMSS Hospital General De Zona N\u0026deg; 2-A, IMSS Hospital General de Zona N\u0026deg; 30, IMSS Hospital General de Zona N\u0026deg; 32, IMSS Hospital General de Zona N\u0026deg; 33, IMSS Hospital General de Zona N\u0026deg; 46, IMSS Hospital General de Zona N\u0026deg; 47, IMSS Hospital General de Zona N\u0026deg; 58, IMSS Hospital General Regional 1 Dr. Carlos Mac Gregor S\u0026aacute;nchez Navarro, IMSS Hospital General Regional 180, IMSS Hospital General Regional 251 Metepec, IMSS Hospital General Regional N\u0026deg; 45, IMSS Hospital General Regional N\u0026deg; 66, IMSS Unidad M\u0026eacute;dica de Atenci\u0026oacute;n Ambulatoria (UMAA), IMSS, Hospital General de Zona N\u0026deg; 6, IMSS, Hospital General de Zona N\u0026deg; 89, IMSS. UMAE No. 1, Instituto de Seguridad y Servicios Sociales de los Trabajadores al Servicio de los Poderes del Estado de Puebla.\u0026nbsp;\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n\u003cli\u003eMcdonald S, Hurst K. \u003cem\u003eFiona Brown Aarti Gulyani Chapter 6 Peritoneal Dialysis 2012 Annual Report-35th Edition\u003c/em\u003e.; 2012.\u003c/li\u003e\n\u003cli\u003eBoudville N, Kemp A, Clayton P, et al. Recent peritonitis associates with mortality among patients treated with peritoneal dialysis. \u003cem\u003eJ Am Soc Nephrol\u003c/em\u003e. 2012;23(8):1398-1405. doi:10.1681/ASN.2011121135\u003c/li\u003e\n\u003cli\u003eSzeto CC, Li PKT. Peritoneal Dialysis-Associated Peritonitis. \u003cem\u003eClin J Am Soc Nephrol\u003c/em\u003e. 2019;14(7):1100-1105. doi:10.2215/CJN.14631218\u003c/li\u003e\n\u003cli\u003eLi PKT, Szeto CC, Piraino B, et al. ISPD peritonitis recommendations: 2016 update on prevention and treatment. \u003cem\u003ePerit Dial Int\u003c/em\u003e. 2016;36(5):481-508. doi:10.3747/pdi.2016.00078\u003c/li\u003e\n\u003cli\u003eAhbap E, Mazi EE, Basturk T, Sakaci T, Aykent MB, Unsal A. Peritoneal dialysis related non-infectious complications: A single-center experience over 20 years. \u003cem\u003eClin Nephrol\u003c/em\u003e. 2023;100(1):19-27. doi:10.5414/CN111092\u003c/li\u003e\n\u003cli\u003eHepburn KS, Lambert K, Mullan J, McAlister B, Lonergan M, Cheikh Hassan HI. Peritoneal dialysis related peritonitis as a risk factor for cardiovascular events. \u003cem\u003eIntern Med J\u003c/em\u003e. Published online February 2020. doi:10.1111/imj.14769\u003c/li\u003e\n\u003cli\u003eTerri M, Trionfetti F, Montaldo C, et al. Mechanisms of Peritoneal Fibrosis: Focus on Immune Cells\u0026ndash;Peritoneal Stroma Interactions. doi:10.3389/fimmu.2021.607204\u003c/li\u003e\n\u003cli\u003ePolanco E, Aquey M, Collado J, et al. A COVID-19 pandemic-specific, structured care process for peritoneal dialysis patients facilitated by telemedicine: Therapy continuity, prevention, and complications management. \u003cem\u003eTher Apher Dial\u003c/em\u003e. 2021;(October 2020):1-9. doi:10.1111/1744-9987.13635\u003c/li\u003e\n\u003cli\u003eCho Y, Johnson DW. Peritoneal dialysis-related peritonitis: towards improving evidence, practices, and outcomes. \u003cem\u003eAm J kidney Dis Off J Natl Kidney Found\u003c/em\u003e. 2014;64(2):278-289. doi:10.1053/j.ajkd.2014.02.025\u003c/li\u003e\n\u003cli\u003eSanabria M, Buitrago G, Lindholm B, et al. Remote patient monitoring program in automated peritoneal dialysis: Impact on hospitalizations. \u003cem\u003ePerit Dial Int\u003c/em\u003e. 2019;39(5):472-478. doi:10.3747/pdi.2018.00287\u003c/li\u003e\n\u003cli\u003eBunch A, Vesga JI, Camargo DO, et al. Remote Automated Peritoneal Dialysis Management in Colombia. \u003cem\u003eKidney Int Reports\u003c/em\u003e. 2019;4(6):873. doi:10.1016/J.EKIR.2019.03.017\u003c/li\u003e\n\u003cli\u003eCuevas-Budhart M\u0026Aacute;, Villeda MT, Delgado AMC, et al. Remote monitoring as a surveillance method in patients on automated peritoneal dialysis for preventing complications and COVID-19 contagion. \u003cem\u003eJ Infect Public Health\u003c/em\u003e. Published online July 27, 2023. doi:10.1016/J.JIPH.2023.07.019\u003c/li\u003e\n\u003cli\u003ePaniagua R, Ramos A, \u0026Aacute;vila M, et al. Remote monitoring of automated peritoneal dialysis reduces mortality, adverse events and hospitalizations: a cluster-randomized controlled trial. \u003cem\u003eNephrol Dial Transplant\u003c/em\u003e. 2025;40(3):588-597. doi:10.1093/NDT/GFAE188\u003c/li\u003e\n\u003cli\u003eLi PKT, Chow KM, Cho Y, et al. ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment. \u003cem\u003ePerit Dial Int\u003c/em\u003e. 2022;42(2):110-153. doi:10.1177/08968608221080586/ASSET/F4B5AEDD-F398-4B08-A7A7-C8E506265EAD/ASSETS/IMAGES/LARGE/10.1177_08968608221080586-FIG10.JPG\u003c/li\u003e\n\u003cli\u003eMilan Manani S, Baretta M, Giuliani A, et al. Remote monitoring in peritoneal dialysis: benefits on clinical outcomes and on quality of life. \u003cem\u003eJ Nephrol\u003c/em\u003e. 2020;33(6):1301-1308. doi:10.1007/s40620-020-00812-2\u003c/li\u003e\n\u003cli\u003eCentellas-P\u0026eacute;rez FJ, Ortega-Cerrato A, Vera M, et al. Impact of Remote Monitoring on Standardized Outcomes in Nephrology-Peritoneal Dialysis. \u003cem\u003eKidney Int reports\u003c/em\u003e. 2023;9(2):266-276. doi:10.1016/J.EKIR.2023.10.034\u003c/li\u003e\n\u003cli\u003eRojas-Diaz M, Ramos A. Help of Remote Patient Monitoring in the Assessment of Changes in Ultrafiltration before, during, and after a Peritonitis Episode in Patients on Automated Peritoneal Dialysis. November 2017. Accessed April 21, 2025. https://www.asn-online.org/education/kidneyweek/2017/program-abstract.aspx?controlId=2784136\u003c/li\u003e\n\u003cli\u003ePraha N, Sriyuktasuth A, Puwarawuttipanit W, Chuengsaman P, Kusakunniran W. Factors Influencing Telehealth Service Use and Health Outcomes in Patients Undergoing Continuous Ambulatory Peritoneal Dialysis: Cross-Sectional Study. \u003cem\u003eJ Med Internet Res\u003c/em\u003e. 2023;25:e48623. doi:10.2196/48623\u003c/li\u003e\n\u003cli\u003ePaniagua R, Ramos A, \u0026Aacute;vila M, et al. Remote monitoring of automated peritoneal dialysis reduces mortality, adverse events, and hospitalizations: a cluster randomized controlled trial. \u003cem\u003eNephrol Dial Transplant\u003c/em\u003e. Published online August 20, 2024. doi:10.1093/NDT/GFAE188\u003c/li\u003e\n\u003cli\u003ePaniagua R, \u0026Aacute;vila-D\u0026iacute;az M, Trejo-Villeda M\u0026Aacute;, Bernal-Amador AS, Ramos A. Utility of remote monitoring in patients on automated peritoneal dialysis. \u003cem\u003eRev Invest Clin\u003c/em\u003e. 2023;75(6):318-326. doi:10.24875/RIC.23000206\u003c/li\u003e\n\u003cli\u003eRuiz IAG. Experience with Remote Monitoring of Automated Peritoneal Dialysis: The First 50 Patients in a Private Peritoneal Dialysis Program in Mexico. \u003cem\u003eJ Am Soc Nephrol\u003c/em\u003e. 2023;34(11S):181-181. doi:10.1681/ASN.20233411S1181B\u003c/li\u003e\n\u003cli\u003eMa L, Zhang C, Gao J, et al. Mortality prediction with adaptive feature importance recalibration for peritoneal dialysis patients. \u003cem\u003ePatterns\u003c/em\u003e. 2023;4(12):100892. doi:10.1016/J.PATTER.2023.100892\u003c/li\u003e\n\u003c/ol\u003e"},{"header":"Tables","content":"\u003cp\u003e\u003cstrong\u003eTable 1. Characteristics of the population by group\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003ctable border=\"0\" cellspacing=\"0\" cellpadding=\"0\" width=\"101%\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 33px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eVariable\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 4px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eTotal\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" valign=\"top\" style=\"width: 19px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eAPD\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"4\" valign=\"top\" style=\"width: 29.156%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eRM-APD\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 33px;\"\u003e\n \u003cp\u003e\u003cstrong\u003en=95\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 4px;\"\u003e\n \u003cp\u003e\u003cstrong\u003en\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eX\u0026plusmn;SD\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u003cstrong\u003en\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 12px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eX\u0026plusmn;SD\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u003cstrong\u003en\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eX\u0026plusmn;SD\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 7px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ep-value\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 33px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eAge\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 4px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e95\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e47.58 \u0026plusmn; 16.26\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e48\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 12px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e52.66 \u0026plusmn; 14.76\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e47\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e42.39 \u0026plusmn; 16.23\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 7px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e.002\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 33px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eGender \u0026nbsp; \u0026nbsp; f (%)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 4px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e48\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 12px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e47\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 7px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 33px;\"\u003e\n \u003cp\u003eMale\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 4px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e69 (71.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 12px;\"\u003e\n \u003cp\u003e37 (77.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e31 (66.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 7px;\"\u003e\n \u003cp\u003e.229\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 33px;\"\u003e\n \u003cp\u003eFemale\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 4px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e27 (28.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 12px;\"\u003e\n \u003cp\u003e11 (22.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e16 (34.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 7px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 33px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eOccupation\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 4px;\"\u003e\n \u003cp\u003e93\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e46\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 12px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e47\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 7px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 33px;\"\u003e\n \u003cp\u003eEmployed\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 4px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e3 1(32.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 12px;\"\u003e\n \u003cp\u003e16 (34.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e15 (31.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 7px;\"\u003e\n \u003cp\u003e.698\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 33px;\"\u003e\n \u003cp\u003eNone\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 4px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e20 (21.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 12px;\"\u003e\n \u003cp\u003e11 (23.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e9 (19.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 7px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 33px;\"\u003e\n \u003cp\u003eHome\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 4px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e14 (14.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 12px;\"\u003e\n \u003cp\u003e6 (13.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e8 (17.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 7px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 33px;\"\u003e\n \u003cp\u003eOwn business\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 4px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e8 (8.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 12px;\"\u003e\n \u003cp\u003e4 (8.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e4 (8.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 7px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 33px;\"\u003e\n \u003cp\u003eLaborer\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 4px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e3 (3.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 12px;\"\u003e\n \u003cp\u003e2 (4.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e1 (2.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 7px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 33px;\"\u003e\n \u003cp\u003eStudent\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 4px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e3 (3.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 12px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e3 (6.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 7px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 33px;\"\u003e\n \u003cp\u003eOther\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 4px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e14 (14.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 12px;\"\u003e\n \u003cp\u003e7 (15.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e7 (14.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 7px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 33px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eMarital status\u003c/strong\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 4px;\"\u003e\n \u003cp\u003e94\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e47\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 12px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e47\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 7px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 33px;\"\u003e\n \u003cp\u003eMarried\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 4px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e56 (58.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 12px;\"\u003e\n \u003cp\u003e32 (68.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e24 (51.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 7px;\"\u003e\n \u003cp\u003e.228\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 33px;\"\u003e\n \u003cp\u003eSingle\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 4px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e22 (23.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 12px;\"\u003e\n \u003cp\u003e19 (19.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e13 (27.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 7px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 33px;\"\u003e\n \u003cp\u003eFree union\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 4px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e7 (7.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 12px;\"\u003e\n \u003cp\u003e1 (2.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e6 (12.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 7px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 33px;\"\u003e\n \u003cp\u003eWidow\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 4px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e5 (5.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 12px;\"\u003e\n \u003cp\u003e3 (6.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e2 (4.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 7px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 33px;\"\u003e\n \u003cp\u003eDivorced\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 4px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e4 (4.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 12px;\"\u003e\n \u003cp\u003e2 (4.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e2 (4.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 7px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 33px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eAcademic level\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 4px;\"\u003e\n \u003cp\u003e92\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e45\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 12px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e47\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 7px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 33px;\"\u003e\n \u003cp\u003eNone\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 4px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e2 (2.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 12px;\"\u003e\n \u003cp\u003e\u0026nbsp;1 (2.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e1 (2.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 7px;\"\u003e\n \u003cp\u003e.802\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 33px;\"\u003e\n \u003cp\u003ePrimary\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 4px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e22 (23.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 12px;\"\u003e\n \u003cp\u003e11 (24.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e11 (23.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 7px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 33px;\"\u003e\n \u003cp\u003eSecondary\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 4px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e29 (30.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 12px;\"\u003e\n \u003cp\u003e15 (33.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e14 (29.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 7px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 33px;\"\u003e\n \u003cp\u003eHigh school\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 4px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e23 (24.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 12px;\"\u003e\n \u003cp\u003e10 (22.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e13 (27.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 7px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 33px;\"\u003e\n \u003cp\u003eVocational\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 4px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e6 (6.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 12px;\"\u003e\n \u003cp\u003e4 (8.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e2 (4.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 7px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 33px;\"\u003e\n \u003cp\u003eProfessional\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 4px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e8 (8.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 12px;\"\u003e\n \u003cp\u003e4 (8.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e4 (8.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 7px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 33px;\"\u003e\n \u003cp\u003ePostgraduate\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 4px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e2 (2.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 12px;\"\u003e\n \u003cp\u003e0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e2 (4.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 7px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 33px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eMonthly Family Income (MXN)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 4px;\"\u003e\n \u003cp\u003e91\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e45\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 12px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e46\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 7px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 33px;\"\u003e\n \u003cp\u003eLess than $2,650\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 4px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e12 (12.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 12px;\"\u003e\n \u003cp\u003e\u0026nbsp;4 (8.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e8 (17.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 7px;\"\u003e\n \u003cp\u003e.335\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 33px;\"\u003e\n \u003cp\u003e$2,651 - $5,301\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 4px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e34 (35.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 12px;\"\u003e\n \u003cp\u003e14 (31.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e20 (43.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 7px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 33px;\"\u003e\n \u003cp\u003e$5,302 - $7,952\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 4px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e27 (28.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 12px;\"\u003e\n \u003cp\u003e16 (35.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e11 (23.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 7px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 33px;\"\u003e\n \u003cp\u003e$7,953 - $10,603\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 4px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e13 (13.7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 12px;\"\u003e\n \u003cp\u003e7 (15.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e6 (13.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 7px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 33px;\"\u003e\n \u003cp\u003e$10,604 - $13,254\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 4px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e3 (3.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 12px;\"\u003e\n \u003cp\u003e2 (4.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e1 (2.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 7px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 33px;\"\u003e\n \u003cp\u003eMore than $13,154\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 4px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e2 (2.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 12px;\"\u003e\n \u003cp\u003e2 (4.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 7px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 33px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSelf-sufficiency\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 4px;\"\u003e\n \u003cp\u003e90\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e47\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 12px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e43\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 7px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 33px;\"\u003e\n \u003cp\u003eYes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 4px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e64 (67.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 12px;\"\u003e\n \u003cp\u003e30 (63.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e34 (79.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 7px;\"\u003e\n \u003cp\u003e.111\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 33px;\"\u003e\n \u003cp\u003eNo\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 4px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e26 (27.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 12px;\"\u003e\n \u003cp\u003e17 (36.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e9 (19.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 7px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 33px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eCatheter type\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 4px;\"\u003e\n \u003cp\u003e92\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e45\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 12px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e47\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 7px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 33px;\"\u003e\n \u003cp\u003eStraight Cuffed\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 4px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e3 (3.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 12px;\"\u003e\n \u003cp\u003e0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e3 (6.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 7px;\"\u003e\n \u003cp\u003e.085\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 33px;\"\u003e\n \u003cp\u003ePig-Tail Cuffed\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 4px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e90 (96.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 12px;\"\u003e\n \u003cp\u003e45 (100)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e44 (93.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 7px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 238px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd style=\"width: 34px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd style=\"width: 102px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd style=\"width: 45px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd style=\"width: 91px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd style=\"width: 45px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd style=\"width: 102px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd style=\"width: 1px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd style=\"width: 56px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e*Renal tuberculosis, preeclampsia, erythematous lupus, renal lithiasis, hypoplasia, eclampsia, renal agenesia, nephrectomy. \u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTable 2. Clinical Characteristics and Laboratory Values by Result\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\" width=\"102%\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 20px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 4px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eTotal\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" valign=\"top\" style=\"width: 24px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eADP\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" valign=\"top\" style=\"width: 25px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eRM-APD\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 7px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eP- V\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 20px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 4px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eN\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 7px;\"\u003e\n \u003cp\u003e\u003cstrong\u003en\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 7px;\"\u003e\n \u003cp\u003e\u003cstrong\u003en\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 7px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003eTemperature (\u0026ordm;C)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 4px;\"\u003e\n \u003cp\u003e95\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e36.33 \u0026plusmn; 0.31\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e48\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e36.36 \u0026plusmn; 0.33\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e47\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e36.29 \u0026plusmn; 0.28\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e0.23\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003eHeart rate (bpm)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 4px;\"\u003e\n \u003cp\u003e93\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e80.43 \u0026plusmn;9.37\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e46\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e79.93 \u0026plusmn; 9.23\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e47\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e80.91 \u0026plusmn; 9.58\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e0.38\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003eSystolic blood pressure (mmHg)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 4px;\"\u003e\n \u003cp\u003e94\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e133.65 \u0026plusmn;19.74\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e48\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e135.73 \u0026plusmn; 19.11\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e46\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e131.48 \u0026plusmn; 20.36\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e0.62\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003eDiastolic blood pressure (mmHg)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 4px;\"\u003e\n \u003cp\u003e93\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e80.22 \u0026plusmn;11.27\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e47\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e80.79 \u0026plusmn; 9.46\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e46\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e79.63 \u0026plusmn; 12.95\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e0.06\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003eWeight (kg)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 4px;\"\u003e\n \u003cp\u003e94\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e72.56 \u0026plusmn;13.76\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e47\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e72.77 \u0026plusmn; 14.02\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e47\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e72.35 \u0026plusmn;13.65\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e0.35\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003eHeight (m)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 4px;\"\u003e\n \u003cp\u003e92\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e164.29 \u0026plusmn;8.36\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e47\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e163.85 \u0026plusmn; 7.78\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e45\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e164.76 \u0026plusmn;9.00\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e0.13\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003eHemoglobin (g/dL)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 4px;\"\u003e\n \u003cp\u003e75\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e10.97 \u0026plusmn;6.92\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e33\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e10.03 \u0026plusmn; 2.18\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e42\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e11.71\u0026plusmn;9.03\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e0.24\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003eHematocrit (%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 4px;\"\u003e\n \u003cp\u003e84\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e27.42\u0026plusmn;10.07\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e40\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e25.86 \u0026plusmn; 10.93\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e44\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e28.84\u0026plusmn;9.13\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e0.09\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003eLeukocytes (cells/mm3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 4px;\"\u003e\n \u003cp\u003e84\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e8717.05\u0026plusmn;13960.44\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e41\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e4956.60\u0026plusmn;4048.91\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e43\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e12302.61\u0026plusmn;18508.58\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e0.39\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003eLymphocytes (Cells/mm3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 4px;\"\u003e\n \u003cp\u003e72\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e3961.62\u0026plusmn;6185.42\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e40\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e3243.73\u0026plusmn;5059.37\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e32\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e4859.00\u0026plusmn;7343.50\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e0.47\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003eNeutrophils (Cells/mm3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 4px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e70\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e10088.13\u0026plusmn;\u003c/strong\u003e\u003cstrong\u003e18754.02\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e38\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e5450.78\u0026plusmn;10478.46\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e32\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e15594.98\u0026plusmn;\u003c/strong\u003e\u003cstrong\u003e24374.81\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.02\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003ePlatelet count (Cells/mcL)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 4px;\"\u003e\n \u003cp\u003e72\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e291.99\u0026plusmn;267.55\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e33\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e338.06\u0026plusmn;76.05\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e39\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e253.01\u0026plusmn;86.46\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e0.10\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003eSerum Glucose (mg/dL)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 4px;\"\u003e\n \u003cp\u003e78\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e129.72\u0026plusmn;82.18\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e37\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e116.19\u0026plusmn;43.02\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e41\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e141.94\u0026plusmn;35.24\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e0.39\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003eSerum Creatinine (mg/24hrs)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 4px;\"\u003e\n \u003cp\u003e86\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e25.56\u0026plusmn;39.15\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e41\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e30.03\u0026plusmn;80.12\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e45\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e21.49\u0026plusmn;79.24\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e0.08\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003eSerum Urea (mg/dL)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 4px;\"\u003e\n \u003cp\u003e88\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e122.19\u0026plusmn;79.92\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e43\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e111.39\u0026plusmn;48.79\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e45\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e132.53\u0026plusmn;41.37\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e1.00\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003eBUN (mg/dL)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 4px;\"\u003e\n \u003cp\u003e67\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e77.33\u0026plusmn;45.29\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e37\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e77.79\u0026plusmn;4.67\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e30\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e76.78\u0026plusmn;6.13\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e0.57\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003eSerum Sodium (mEq/L)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 4px;\"\u003e\n \u003cp\u003e65\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e135.94\u0026plusmn;5.42\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e32\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e135.66\u0026plusmn;19.34\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e33\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e136.21\u0026plusmn;32.26\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e0.58\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003eSerum Potassium (mEp/L)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 4px;\"\u003e\n \u003cp\u003e71\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e9.44\u0026plusmn;26.50\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e35\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e9.01\u0026plusmn;37.43\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e36\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e9.87\u0026plusmn;32.65\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e0.74\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003eSerum Chloride (mEp/L)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 4px;\"\u003e\n \u003cp\u003e74\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e86.27\u0026plusmn;34.79\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e34\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e83.35\u0026plusmn;31.58\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e40\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e88.76\u0026plusmn;31.02\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e0.25\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003eSerum total Calcium (mg/dL)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 4px;\"\u003e\n \u003cp\u003e61\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e20.33\u0026plusmn;31.04\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e30\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e20.46\u0026plusmn;3.49\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e31\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e20.22\u0026plusmn;7.88\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e0.90\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 20px;\"\u003e\n \u003cp\u003ePhosphorous (mg/dL)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 4px;\"\u003e\n \u003cp\u003e61\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e6.69\u0026plusmn;6.02\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e31\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e6.33\u0026plusmn;2.18\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e30\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 17px;\"\u003e\n \u003cp\u003e7.08\u0026plusmn;9.03\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e0.24\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTable 3. Peritonitis rates by group.\u003c/strong\u003e\u003c/p\u003e\n\u003ctable border=\"0\" cellspacing=\"0\" cellpadding=\"0\" width=\"100%\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 43px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 18px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 18px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eADP\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 18px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eRM-APD\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 43px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;All peritonitis in the studied population*\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 18px;\"\u003e\n \u003cp\u003e120\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 18px;\"\u003e\n \u003cp\u003e54\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 18px;\"\u003e\n \u003cp\u003e65\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 43px;\"\u003e\n \u003cp\u003ePeritonitis rate*\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 18px;\"\u003e\n \u003cp\u003e0.17\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 18px;\"\u003e\n \u003cp\u003e0.19\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 18px;\"\u003e\n \u003cp\u003e0.15\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 43px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eFirst peritonitis\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 18px;\"\u003e\n \u003cp\u003e95\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 18px;\"\u003e\n \u003cp\u003e48\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 18px;\"\u003e\n \u003cp\u003e47\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 43px;\"\u003e\n \u003cp\u003eFirs peritonitis rate\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 18px;\"\u003e\n \u003cp\u003e0.12\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 18px;\"\u003e\n \u003cp\u003e0.12\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 18px;\"\u003e\n \u003cp\u003e0.11\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 43px;\"\u003e\n \u003cp\u003eEvent/100 patients∙year\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 18px;\"\u003e\n \u003cp\u003e12\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 18px;\"\u003e\n \u003cp\u003e12\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 18px;\"\u003e\n \u003cp\u003e11\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 43px;\"\u003e\n \u003cp\u003eFollow-up months/patient\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 18px;\"\u003e\n \u003cp\u003e102.06\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 18px;\"\u003e\n \u003cp\u003e97.59\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 18px;\"\u003e\n \u003cp\u003e106.77\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 43px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSecond peritonitis\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 18px;\"\u003e\n \u003cp\u003e17\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 18px;\"\u003e\n \u003cp\u003e9\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 18px;\"\u003e\n \u003cp\u003e8\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 43px;\"\u003e\n \u003cp\u003eEvent/100 patients∙year\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 18px;\"\u003e\n \u003cp\u003e2.00\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 18px;\"\u003e\n \u003cp\u003e1.90\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 18px;\"\u003e\n \u003cp\u003e1.40\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 43px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eThird Peritonitis\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 18px;\"\u003e\n \u003cp\u003e8\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 18px;\"\u003e\n \u003cp\u003e7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 18px;\"\u003e\n \u003cp\u003e1\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 43px;\"\u003e\n \u003cp\u003eEvent/100 patients∙year\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 18px;\"\u003e\n \u003cp\u003e0.9\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 18px;\"\u003e\n \u003cp\u003e1.8\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 18px;\"\u003e\n \u003cp\u003e0.2\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 43px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eHospitalized\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 18px;\"\u003e\n \u003cp\u003e55\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 18px;\"\u003e\n \u003cp\u003e29\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 18px;\"\u003e\n \u003cp\u003e26\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 43px;\"\u003e\n \u003cp\u003eEvent/100 patients∙year\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 18px;\"\u003e\n \u003cp\u003e6.38\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 18px;\"\u003e\n \u003cp\u003e7.43\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 18px;\"\u003e\n \u003cp\u003e6.22\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 43px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eDropout\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 18px;\"\u003e\n \u003cp\u003e35\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 18px;\"\u003e\n \u003cp\u003e19\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 18px;\"\u003e\n \u003cp\u003e16\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 43px;\"\u003e\n \u003cp\u003eEvent/100 patients∙year\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 18px;\"\u003e\n \u003cp\u003e4.33\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 18px;\"\u003e\n \u003cp\u003e4.70\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 18px;\"\u003e\n \u003cp\u003e3.68\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e*Original study from Paniagua R et al. \u003csup\u003e19\u003c/sup\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTable 4.\u0026nbsp;\u003c/strong\u003e\u003cstrong\u003eComparison of clinical outcomes between therapy remote monitoring APD and Conventional APD\u003c/strong\u003e\u003c/p\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\" width=\"108%\" class=\"fr-table-selection-hover\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 19px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 3px;\"\u003e\n \u003cp\u003e\u003cstrong\u003en\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 15px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eTOTAL\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 3px;\"\u003e\n \u003cp\u003e\u003cstrong\u003en\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026sum;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eAPD\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026sum;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 3px;\"\u003e\n \u003cp\u003e\u003cstrong\u003en\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eRM-APD\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026sum;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 5px;\"\u003e\n \u003cp\u003e\u003cstrong\u003ep-v\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 19px;\"\u003e\n \u003cp\u003eTotal\u003cstrong\u003e,\u003c/strong\u003e Programmed Volume (ml)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 3px;\"\u003e\n \u003cp\u003e75\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 15px;\"\u003e\n \u003cp\u003e10,300 \u0026plusmn; 1,508\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 3px;\"\u003e\n \u003cp\u003e34\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e10,338 \u0026plusmn; 1,636\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 3px;\"\u003e\n \u003cp\u003e41\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e10,268 \u0026plusmn; 1,414\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 5px;\"\u003e\n \u003cp\u003e0.37\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 19px;\"\u003e\n \u003cp\u003ePrescribed Cycles\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 3px;\"\u003e\n \u003cp\u003e75\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 15px;\"\u003e\n \u003cp\u003e4.45 \u0026plusmn; 0.57\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 3px;\"\u003e\n \u003cp\u003e34\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e4.47 \u0026plusmn; 0.56\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 3px;\"\u003e\n \u003cp\u003e41\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e4.44 \u0026plusmn; 0.59\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 5px;\"\u003e\n \u003cp\u003e0.65\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 19px;\"\u003e\n \u003cp\u003eProgrammed Infusion Volume (ml)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 3px;\"\u003e\n \u003cp\u003e75\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 15px;\"\u003e\n \u003cp\u003e2,066 \u0026plusmn; 194.05\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 3px;\"\u003e\n \u003cp\u003e34\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e2,038 \u0026plusmn; 208.91\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 3px;\"\u003e\n \u003cp\u003e41\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e2,090 \u0026plusmn; 180.00\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 5px;\"\u003e\n \u003cp\u003e0.46\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 19px;\"\u003e\n \u003cp\u003eThe last Prescribed Infusion Volume (ml)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 3px;\"\u003e\n \u003cp\u003e49\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 15px;\"\u003e\n \u003cp\u003e1,580\u0026nbsp;\u0026plusmn; 614.81\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 3px;\"\u003e\n \u003cp\u003e26\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e1,525 \u0026plusmn; 668.02\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 3px;\"\u003e\n \u003cp\u003e23\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e1,643 \u0026plusmn; 556.63\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 5px;\"\u003e\n \u003cp\u003e0.44\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 19px;\"\u003e\n \u003cp\u003eActual Cycles\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 3px;\"\u003e\n \u003cp\u003e75\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 15px;\"\u003e\n \u003cp\u003e4.35 \u0026plusmn; 0.59\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 3px;\"\u003e\n \u003cp\u003e34\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e4.38 \u0026plusmn; 0.58\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 3px;\"\u003e\n \u003cp\u003e41\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e4.33\u0026nbsp;\u0026plusmn; 0.61\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 5px;\"\u003e\n \u003cp\u003e0.80\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 19px;\"\u003e\n \u003cp\u003eNight dwell Volume (ml)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 3px;\"\u003e\n \u003cp\u003e75\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 15px;\"\u003e\n \u003cp\u003e2,022 \u0026plusmn; 308.81\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 3px;\"\u003e\n \u003cp\u003e34\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e1,956 \u0026plusmn; 4009.27\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 3px;\"\u003e\n \u003cp\u003e41\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e2,076\u0026nbsp;\u0026plusmn;\u0026nbsp;177.75\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 5px;\"\u003e\n \u003cp\u003e0.40\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 19px;\"\u003e\n \u003cp\u003eWet day Infusion Volume (ml)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 3px;\"\u003e\n \u003cp\u003e49\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 15px;\"\u003e\n \u003cp\u003e1,544 \u0026plusmn; 599.91\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 3px;\"\u003e\n \u003cp\u003e26\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e1481.56 \u0026plusmn; 647.35\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 3px;\"\u003e\n \u003cp\u003e23\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e1615.85 \u0026plusmn; 546.83\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 5px;\"\u003e\n \u003cp\u003e0.50\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 19px;\"\u003e\n \u003cp\u003eInitial Drain Volume (ml)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 3px;\"\u003e\n \u003cp\u003e75\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 15px;\"\u003e\n \u003cp\u003e818.50 \u0026plusmn; 732.73\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 3px;\"\u003e\n \u003cp\u003e34\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e903.74 \u0026plusmn; 631.73\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 3px;\"\u003e\n \u003cp\u003e41\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e747.82\u0026nbsp;\u0026plusmn;\u0026nbsp;807.91\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 5px;\"\u003e\n \u003cp\u003e0.26\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 19px;\"\u003e\n \u003cp\u003eActual Overnight Ultrafiltration (ML)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 3px;\"\u003e\n \u003cp\u003e75\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 15px;\"\u003e\n \u003cp\u003e655.11 \u0026plusmn; 392.35\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 3px;\"\u003e\n \u003cp\u003e34\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e754.48 \u0026plusmn; 387.88\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 3px;\"\u003e\n \u003cp\u003e41\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e572.71\u0026nbsp;\u0026plusmn;\u0026nbsp;381.20\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 5px;\"\u003e\n \u003cp\u003e0.81\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 19px;\"\u003e\n \u003cp\u003eActual Total Ultrafiltration (ml)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 3px;\"\u003e\n \u003cp\u003e45\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 15px;\"\u003e\n \u003cp\u003e415.01 \u0026plusmn; 512.13\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 3px;\"\u003e\n \u003cp\u003e25\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e409.77 \u0026plusmn; 553.97\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 3px;\"\u003e\n \u003cp\u003e20\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e421.56\u0026nbsp;\u0026plusmn;\u0026nbsp;468.69\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 5px;\"\u003e\n \u003cp\u003e0.15\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 19px;\"\u003e\n \u003cp\u003eYellow Flags\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 3px;\"\u003e\n \u003cp\u003e73\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 15px;\"\u003e\n \u003cp\u003e7.47 \u0026plusmn; 7.01\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 3px;\"\u003e\n \u003cp\u003e34\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e545\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e7.79 \u0026plusmn; 8.38\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e265\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 3px;\"\u003e\n \u003cp\u003e39\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e7.18 \u0026plusmn; 5.68\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e280\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 5px;\"\u003e\n \u003cp\u003e0.75\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 19px;\"\u003e\n \u003cp\u003eEvents During Treatment (Number)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 3px;\"\u003e\n \u003cp\u003e53\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 15px;\"\u003e\n \u003cp\u003e3.89 \u0026plusmn; 4.23\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 3px;\"\u003e\n \u003cp\u003e25\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e206\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e3.80 \u0026plusmn; 4.31\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e95\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 3px;\"\u003e\n \u003cp\u003e28\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e3.96 \u0026plusmn; 4.23\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e111\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 5px;\"\u003e\n \u003cp\u003e0.09\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 19px;\"\u003e\n \u003cp\u003eEvents during treatment (sum)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 3px;\"\u003e\n \u003cp\u003e53\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 15px;\"\u003e\n \u003cp\u003e24.77 \u0026plusmn; 28.07\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 3px;\"\u003e\n \u003cp\u003e25\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e1313\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e24.44 \u0026plusmn; 28.99\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e611\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 3px;\"\u003e\n \u003cp\u003e28\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e25.07 \u0026plusmn;27.75\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e702\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 5px;\"\u003e\n \u003cp\u003e0.06\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 19px;\"\u003e\n \u003cp\u003eRed Flags\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 3px;\"\u003e\n \u003cp\u003e69\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 15px;\"\u003e\n \u003cp\u003e13.86 \u0026plusmn; 11.50\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 3px;\"\u003e\n \u003cp\u003e31\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e956\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e14.19 \u0026plusmn; 11.57\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e440\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 3px;\"\u003e\n \u003cp\u003e38\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e13.58 \u0026plusmn; 11.59\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e516\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 5px;\"\u003e\n \u003cp\u003e0.64\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 19px;\"\u003e\n \u003cp\u003eEvents during treatment (number)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 3px;\"\u003e\n \u003cp\u003e31\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 15px;\"\u003e\n \u003cp\u003e2.61 \u0026plusmn; 2.67\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 3px;\"\u003e\n \u003cp\u003e14\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e81\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e2.79 \u0026plusmn; 3.64\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e39\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 3px;\"\u003e\n \u003cp\u003e17\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e2.47 \u0026plusmn; 1.59\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e42\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 5px;\"\u003e\n \u003cp\u003e0.66\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 19px;\"\u003e\n \u003cp\u003eEvents during treatment (sum)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 3px;\"\u003e\n \u003cp\u003e31\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 15px;\"\u003e\n \u003cp\u003e50.94 \u0026plusmn; 78.20\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 3px;\"\u003e\n \u003cp\u003e14\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e1579\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e65.07 \u0026plusmn; 112.04\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e911\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 3px;\"\u003e\n \u003cp\u003e17\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e39.29 \u0026plusmn; 30.76\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e668\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 5px;\"\u003e\n \u003cp\u003e0.73\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 19px;\"\u003e\n \u003cp\u003eAlarms\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 3px;\"\u003e\n \u003cp\u003e75\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 15px;\"\u003e\n \u003cp\u003e63.16 \u0026plusmn; 67.27\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 3px;\"\u003e\n \u003cp\u003e34\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e4737\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e68.76 \u0026plusmn; 67.11\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e2338\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 3px;\"\u003e\n \u003cp\u003e41\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e58.51 \u0026plusmn; 45.40\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e2399\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 5px;\"\u003e\n \u003cp\u003e0.19\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 19px;\"\u003e\n \u003cp\u003eDays of connection\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 3px;\"\u003e\n \u003cp\u003e75\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 15px;\"\u003e\n \u003cp\u003e25.53 \u0026plusmn; 6.23\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 3px;\"\u003e\n \u003cp\u003e34\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e1915\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e24.50 \u0026plusmn; 6.84\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e833\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 3px;\"\u003e\n \u003cp\u003e41\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 14px;\"\u003e\n \u003cp\u003e26.39 \u0026plusmn; 5.16\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 6px;\"\u003e\n \u003cp\u003e1082\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 5px;\"\u003e\n \u003cp\u003e0.45\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"Remote monitoring, Peritoneal Dialysis, Peritonitis, Remote Consultation, Telemedicine, Treatment Outcome","lastPublishedDoi":"10.21203/rs.3.rs-6993883/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-6993883/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003e\u003cstrong\u003eBackground: \u003c/strong\u003ePeritonitis remains the most serious complication of peritoneal dialysis (PD), often resulting in hospitalization, technique failure, and increased mortality. Remote monitoring (RM) in automated peritoneal dialysis (APD) provides fast and opportune access to treatment data, potentially enabling earlier clinical intervention.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAim: \u003c/strong\u003eTo assess whether RM modifies the clinical course of peritonitis in APD patients by evaluating the time to first episode, hospitalization outcomes, and ultrafiltration (UF) dynamics.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eMethods: \u003c/strong\u003eThis secondary analysis of a cluster randomized controlled trial included 801 APD patients (403 with RM, 398 with conventional APD) followed from 2018 to 2020. A total of 95 patients with confirmed peritonitis were analyzed. Clinical variables and UF trends from the Sharesource® platform were assessed for the 10 days before and after the peritonitis diagnosis. Survival was evaluated using Kaplan–Meier curves and multivariable Cox regression models.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eResults: \u003c/strong\u003eRM-APD patients experienced a significantly longer time to first peritonitis episode (13.3 vs. 11.7 months; p \u0026lt; 0.001). Although there were no significant differences in overall peritonitis incidence, hospitalization, or mortality rates, RM-APD patients showed improved post-hospitalization survival (p = 0.003) and lower therapy dropout after infection (p = 0.001). UF trends suggested a pre-infection decline, though not statistically significant.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConclusion: \u003c/strong\u003eRM does not reduce peritonitis incidence but appears to enable earlier detection and improved outcomes, supporting a shift toward proactive management in APD. Future research should explore predictive algorithms based on RM-derived data to enhance peritonitis care.\u003c/p\u003e","manuscriptTitle":"Remote Monitoring in Automated Peritoneal Dialysis Modifies the Clinical Course of Peritonitis: A Secondary Analysis of a Cluster Randomized Trial","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2025-09-22 08:46:06","doi":"10.21203/rs.3.rs-6993883/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"6f8f6ca6-b765-4d73-bd3b-16cf44bf2465","owner":[],"postedDate":"September 22nd, 2025","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[],"tags":[],"updatedAt":"2025-09-24T17:38:29+00:00","versionOfRecord":[],"versionCreatedAt":"2025-09-22 08:46:06","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-6993883","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-6993883","identity":"rs-6993883","version":["v1"]},"buildId":"XKTyCvWXoU3ODBz1xrDgd","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}